Third Dose of COVID-19 Vaccine Appears Least Effective for Lymphoma Patients
Vaccine effectiveness against breakthrough SARS-CoV-2 infections was 10.5% for patients with lymphoma.
Hematologic Cancers
Real-World Treatment Outcomes, Roles of Transplant and Maintenance Rituximab in Mantle Cell Lymphoma
ASCT as first-line treatment for patients with MCL appears to be underutilized in the US community setting.
Fibrinogen May Be Associated With Poor Prognosis in Myelodysplastic Syndrome
Researchers sought to determine the role of fibrinogen levels in patients with myelodysplastic syndrome.
Blood Type Linked to Outcomes of Immune Checkpoint Inhibitor Therapy in Metastatic Cancer
Blood type may influence response to immune checkpoint inhibitor therapy among patients with metastatic cancer, a study suggests.
Enasidenib in Relapsed/Refractory IDH2-Mutated Acute Myeloid Leukemia
Enasidenib did not improve overall survival, but it was associated with improvements in event-free survival and time to treatment failure.
Measuring Circulating Tumor Cells at Diagnosis Can Improve Risk Stratification in Multiple Myeloma
Circulating tumor cell levels were an independent predictor of progression-free survival and overall survival.
Mosunetuzumab Demonstrates Activity in Relapsed/Refractory Follicular Lymphoma
Mosunetuzumab produced an objective response rate of 80%.
Post-Transplant Prognostic Model Developed for Myelodysplastic Syndromes
Researchers developed a clinical risk model for predicting outcomes of allogeneic transplant in patients with MDS.
Survival Advantage Seen for A+ADV in Advanced Hodgkin Lymphoma
Brentuximab vedotin prolonged progression-free survival and overall survival in patients with stage III/IV Hodgkin lymphoma.
Generic Equivalent to Istodax Now Available
Romidepsin is a histone deacetylase inhibitor indicated for the treatment of cutaneous T-cell lymphoma.
- Loading...
Loading...
Next post in Lymphoma
Loading... 
Loading...